This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Boehringer Ingelheim are taking on cancer through a dedicated commitment to delivering first-in-class cancer-cell directed therapies, innovative immuno-oncology strategies and smart combination approaches. Our goal is to achieve cancer breakthroughs that give hope to patients. Find out more about our oncology clinical trial programme and long-term research commitment below.
| Compound and target | LATEST DEVELOPMENT PHASE | |||
|---|---|---|---|---|
| Phase I | Phase II | Phase III | Approved | |
| Cancer cell-directed and immuno-oncology therapies | ||||
|
Afatinib |
NSCLC
A
Approved
|
|||
|
Nintedanib |
NSCLC
A
Approved
|
|||
|
Xentuzumab (BI 836845) |
NSCLC
1
Phase I
Breast cancer
1
Phase I
|
Breast cancer
2
Phase II
|
||
|
PD-1 inhibitor (BI 754091) |
Solid tumours
1
Phase I
|
Solid tumours
2
Phase II
|
||
|
LAG-3 inhibitor (BI 754111) |
Solid tumours
1
Phase I
|
Solid tumours
2
Phase II
|
||
|
VEGF/Ang2 inhibitor (BI 836880) |
Solid tumours
1
Phase I
|
|||
|
BET inhibitor (BI 894999) |
Solid tumours
1
Phase I
|
|||
|
SMAC mimetic (BI 891065) |
Solid tumours
1
Phase I
|
|||
|
MDM2-p53 antagonist |
Solid tumours
1
Phase I
|
|||
|
SIRP alpha myeloid checkpoint inhibitor |
Solid tumours
1
Phase I
|
|||
|
LRP5/6 antagonist (BI 905677) |
Solid tumours
1
Phase I
|
|||
|
mRNA-based cancer vaccine (BI 1361849) |
NSCLC
1
Phase I
|
|||
|
SOS1::KRAS inhibitor (in preparation) |
||||
|
STING agonist (in preparation) |
||||
|
TRAILR2/CDH17 antibody (in preparation) |
||||
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information..
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here.
Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063, BI 1361849, SOS1::KRAS inhibitor, STING agonist and TRAILR2/CDH17 antibody are investigational compounds and have not been approved. Their safety and efficacy have not been established.
Ang2, angiopoietin 2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; CDH17, cell anchor cadherin 17; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; KRAS, Kirsten rat sarcoma; LAG-3, lymphocyte activation gene 3 protein; LRP5/6, lipoprotein receptor-related protein 5/6; MDM2, murine double minute 2 protein; mRNA, messenger ribonucleic acid; NSCLC: non-small-cell lung carcinoma; PD-1, programmed cell death protein-1; PDGFR, platelet-derived growth factor receptor; SIRPα, signal-regulatory protein alpha; SMAC, second mitochondria-derived activator of caspase; SOS1, Son of sevenless homolog 1; STING, small molecule agonist of the stimulator of interferon genes; TRAILR2, tumour necrosis factor-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: August 2019
Prescribing Information: GIOTRIF®. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf (Accessed: June 2019)
Prescribing Information: VARGATEF®. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: June 2019)
ClinicalTrials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/NCT03099174 (Accessed: June 2019)
ClinicalTrials.gov. NCT02123823. https://clinicaltrials.gov/ct2/show/NCT02123823 (Accessed: June 2019)
ClinicalTrials.gov. NCT03659136. https://clinicaltrials.gov/ct2/show/NCT03659136 (Accessed: June 2019)
ClinicalTrials.gov. NCT03207191. https://clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: June 2019)
ClinicalTrials.gov. NCT02632721. https://clinicaltrials.gov/ct2/show/NCT02632721 (Accessed: June 2019)
ClinicalTrials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: June 2019)
ClinicalTrials.gov. NCT03468426. https://clinicaltrials.gov/ct2/show/NCT03468426 (Accessed: June 2019)
ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/ct2/show/NCT02952248 (Accessed: June 2019)
ClinicalTrials.gov. NCT03156114. https://clinicaltrials.gov/ct2/show/NCT03156114 (Accessed: June 2019)
ClinicalTrials.gov. NCT03780725. https://clinicaltrials.gov/ct2/show/NCT03780725 (Accessed: June 2019)
ClinicalTrials.gov. NCT03433898. https://clinicaltrials.gov/ct2/show/NCT03433898 (Accessed: June 2019)
ClinicalTrials.gov. NCT03166631. https://clinicaltrials.gov/ct2/show/NCT03166631 (Accessed: June 2019)
ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: June 2019)
ClinicalTrials.gov. NCT02674152. https://clinicaltrials.gov/ct2/show/NCT02674152 (Accessed: June 2019)
ClinicalTrials.gov. NCT02689505. https://clinicaltrials.gov/ct2/show/NCT02689505 (Accessed: June 2019)
ClinicalTrials.gov. NCT02516553. https://clinicaltrials.gov/ct2/show/NCT02516553 (Accessed: June 2019)
ClinicalTrials.gov. NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381 (Accessed: June 2019)
ClinicalTrials.gov. NCT03604445. https://clinicaltrials.gov/ct2/show/NCT03604445 (Accessed: June 2019)
ClinicalTrials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/NCT03164772 (Accessed: June 2019)
Boehringer Ingelheim. Data on file.
Boehringer Ingelheim. Data on file.
Boehringer Ingelheim. Data on file.